Nanotherapeutics

Your Biopharmaceutical Development and Manufacturing Partner

XOMA's divests biodefense program to Nanotherapeutics, Inc.

BERKELEY, Calif., Nov. 5, 2015 -- XOMA Corporation (XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has agreed to sell its biologics manufacturing facilities, equipment, and associated real estate to Agenus Inc. (AGEN). The transaction is expected to close in December 2015. In conjunction with the transaction, Agenus will offer employment to a select team of XOMA employees currently operating the facilities and may provide small-scale manufacturing services for XOMA in the future.

Read Full article at XOMA

Copyright 2016 NANOTHERAPEUTICS, INC.  All rights reserved.